THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [8.33] ID: TIP-MED-000161 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Itraconazole & Voriconazole

Active Ingredient / Scientific Identity: Itraconazole & Voriconazole • Class: Systemic Triazole Ergosterol (CYP51A1) Synthesis Inhibitor Antifungals — Potent CYP3A4 Inhibitors (Schedule H | NLEM 2022)

⚖️ Compare Profile
Generic / Entity NameItraconazole & Voriconazole ([8.33])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassSystemic Triazole Ergosterol (CYP51A1) Synthesis Inhibitor Antifungals — Potent CYP3A4 Inh
Available Dosage FormsItraconazole Capsules: Conventional 100 mg, 200 mg; SUBA Capsules: 50 mg, 65 mg, 130 mg (SUBA 65 mg = Conventi
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Oral Voriconazole requires no adjustment in CKD, BUT IV Voriconazole contains SBECD vehicle which accumulates when CrC
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Itraconazole & Voriconazole (TIP-MED-000161, Reference Code [8.33]) is classified under Antimicrobials — Systemic Antifungal Agents (Ch 08) as a Systemic Triazole Ergosterol (CYP51A1) Synthesis Inhibitor Antifungals — Potent CYP3A4 Inhibitors (Schedule H | NLEM 2022). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.33], p. 109): Itraconazole: Canditral (Glenmark), Sporanox (J&J), Itrasys, SUBA-Itraconazole: Itratuf / Lozanoc (50/65/130 mg). Voriconazole: Vorier (Zydus), Vfend (Pfizer), Voritek (Cipla) — Strengths & Dosage Forms: Itraconazole Capsules: Conventional 100 mg, 200 mg; SUBA Capsules: 50 mg, 65 mg, 130 mg (SUBA 65 mg = Conventional 100 mg!). Voriconazole Tablets: 50 mg, 200 mg; IV Vial: 200 mg
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.33], p. 109): Itraconazole: Canditral (Glenmark), Sporanox (J&J), Itrasys, SUBA-Itraconazole: Itratuf / Lozanoc (50/65/130 mg). Voriconazole: Vorier (Zydus), Vfend (Pfizer), Voritek (Cipla) — Strengths & Dosage Forms: Itraconazole Capsules: Conventional 100 mg, 200 mg; SUBA Capsules: 50 mg, 65 mg, 130 mg (SUBA 65 mg = Conventional 100 mg!). Voriconazole Tablets: 50 mg, 200 mg; IV Vial: 200 mg
Dosage Forms & Available Strengths:
Itraconazole Capsules: Conventional 100 mg, 200 mg; SUBA Capsules: 50 mg, 65 mg, 130 mg (SUBA 65 mg = Conventional 100 mg!). Voriconazole Tablets: 50 mg, 200 mg; IV Vial: 200 mg
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Systemic Triazole Ergosterol (CYP51A1) Synthesis Inhibitor Antifungals — Potent CYP3A4 Inhibitors (Schedule H | NLEM 2022) acting on target receptor/enzyme pathways in Antimicrobials — Systemic Antifungal Agents (Ch 08): clinical efficacy is mediated via Systemic Triazole Ergosterol (CYP51A1) Synthesis Inhibitor Antifungals — Potent CYP3A4 Inhibitors (Schedule H | NLEM 2022) for Itraconazole: Extensive/recalcitrant dermatophytosis (tinea corporis/cruris/onychomycosis), sporotrichosis, histoplasmosis, ABPA. Voriconazole: First-line drug of choice for Invasive Aspergillosis, Candida krusei/glabrata, and Fusarium infections.

4. Therapeutic Indications & Evidence-Supported Uses

  • Itraconazole: Extensive/recalcitrant dermatophytosis (tinea corporis/cruris/onychomycosis), sporotrichosis, histoplasmosis, ABPA
  • Voriconazole: First-line drug of choice for Invasive Aspergillosis, Candida krusei/glabrata, and Fusarium infections

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Itraconazole (Conventional): Tinea: 100–200 mg PO OD–BD for 2–4 weeks; Onychomycosis: 200 mg BD x 7d/month for 2–3 pulses (SUBA: 65–130 mg OD–BD). Voriconazole (Adults >=40 kg): Load 400 mg PO (or 6 mg/kg IV) q12h x 2 doses on Day 1, then Maintenance 200 mg PO (or 4 mg/kg IV) q12h

Administration & Meal Timing: OPPOSITE FOOD & ACID RULES: (1) Conventional Itraconazole (100/200 mg) MUST BE TAKEN IMMEDIATELY AFTER A FULL MEAL AND REQUIRES GASTRIC ACID (SUBA-Itraconazole does not require acid/food). (2) Oral Voriconazole MUST BE TAKEN ON AN EMPTY STOMACH (1h before or 2h after a meal)! | Morning & Evening (12-hourly BD) or OD (Itraconazole)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Oral Voriconazole requires no adjustment in CKD, BUT IV Voriconazole contains SBECD vehicle which accumulates when CrCl <50 mL/min -> switch to Oral Voriconazole if CrCl <50 mL/min! Hepatic: In Child–Pugh A/B cirrhosis, give standard Day-1 Voriconazole load, then HALVE maintenance dose (100 mg BD)!
Elimination & Renal Adjustment:
Renal: Oral Voriconazole requires no adjustment in CKD, BUT IV Voriconazole contains SBECD vehicle which accumulates when CrCl <50 mL/min -> switch to Oral Voriconazole if CrCl <50 mL/min! Hepatic: In Child–Pugh A/B cirrhosis, give standard Day-1 Voriconazole load, then HALVE maintenance dose (100 mg BD)!
Hepatic Impairment Considerations:
Renal: Oral Voriconazole requires no adjustment in CKD, BUT IV Voriconazole contains SBECD vehicle which accumulates when CrCl <50 mL/min -> switch to Oral Voriconazole if CrCl <50 mL/min! Hepatic: In Child–Pugh A/B cirrhosis, give standard Day-1 Voriconazole load, then HALVE maintenance dose (100 mg BD)!

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • BOXED WARNINGS: (1) Itraconazole has negative inotropic effects and is CONTRAINDICATED in Heart Failure (HFrEF) and pregnancy. (2) Both are among the MOST POTENT CYP3A4 INHIBITORS in medicine — contraindicated with Simvastatin, Lovastatin, Atorvastatin (>20 mg), Ticagrelor, Ivabradine, Ranolazine, Eplerenone, Dabigatran, Rivaroxaban, Colchicine, Domperidone, Quetiapine, Midazolam, and Ergotamine!

Key Clinical Precautions: Renal: Oral Voriconazole requires no adjustment in CKD, BUT IV Voriconazole contains SBECD vehicle which accumulates when CrCl <50 mL/min -> switch to Oral Voriconazole if CrCl <50 mL/min! Hepatic: In Child–Pugh A/B cirrhosis, give standard Day-1 Voriconazole load, then HALVE maintenance dose (100 mg BD)!

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Itraconazole: Nausea, abdominal pain, headache, ankle oedema, hypertension, hypokalaemia. Voriconazole: Transient visual disturbances (30% — blurred vision, altered colour perception within 30m of dose, lasting ~30m!), photosensitivity rash, hallucinations, transaminitis
  • Acute Congestive Heart Failure (Itraconazole), severe hepatotoxicity/acute liver failure (both), QTc prolongation / Torsades de Pointes, visual hallucinations & encephalopathy, peripheral neuropathy
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • PPIs, H2RAs, and Antacids reduce Conventional Itraconazole absorption by 50–70%! Rifampicin, Carbamazepine, and Phenytoin reduce Itraconazole & Voriconazole levels to zero (contraindicated!)
  • Both markedly increase Tacrolimus, Cyclosporine, Sirolimus, Warfarin, Sulfonylureas, Digoxin, CCBs, and Budesonide/Fluticasone inhalers!

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: CRITICAL COUNTER DISTINCTIONS: (1) Verify whether Itraconazole is Conventional 100/200 mg (must take right after a full meal; avoid PPIs!) or SUBA 65/130 mg; (2) Pause Atorvastatin/Simvastatin during Itraconazole therapy; (3) For Voriconazole (Vorier): take on an empty stomach 1h before food, do not drive at night if vision blurs, and wear strict sun protection
  • Meal & Clock Timing Instruction: OPPOSITE FOOD & ACID RULES: (1) Conventional Itraconazole (100/200 mg) MUST BE TAKEN IMMEDIATELY AFTER A FULL MEAL AND REQUIRES GASTRIC ACID (SUBA-Itraconazole does not require acid/food). (2) Oral Voriconazole MUST BE TAKEN ON AN EMPTY STOMACH (1h before or 2h after a meal)! (Morning & Evening (12-hourly BD) or OD (Itraconazole))
  • Missed Dose Protocol: Take as soon as remembered unless within 4h of next dose
  • Geriatric Dispensing Pearl: Screen older adults for heart failure, CCBs, Statins, and anticoagulants before dispensing Itraconazole

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Itraconazole Capsules: Conventional 100 mg, 200 mg; SUBA Capsules: 50 mg, 65 mg, 130 mg (SUBA 65 mg = Conventional 100 mg!). Voriconazole Tablets: 50 mg, 200 mg; IV Vial: 200 mg

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.33] (p. 109)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.